An Update on Lipoprotein(a) and Lipid-apheresis
An Update on Lipoprotein(a) and Lipid-apheresis is organized by Opus Medicus, Inc.
Course Dates:
Offered Date: 06-Apr-2022
Expiration Date: 05-Apr-2025
Description:
Elevated Lp(a) level, which is associated with an increased risk of cardiovascular disease (CVD), is estimated to affect 20%-30% of the world's population. Presently, no medication is approved by the FDA to lower Lp(a) and CVD risk. The future holds promise of newer therapies to lower Lp(a) but until then lipid-apheresis remains the only option for the treatment of elevated Lp(a) and CVD.
Objectives:
• The structure and normal metabolism of lipoprotein(a).
• The associative risk of cardiovascular disease with elevated LP(a).
• The prevalence and mechanism of action of elevated Lp(a) levels.
• Present and potential future therapeutic options for elevated Lp(a).
Topics:
• Structure of lipoprotein(a).
• Relationship between Lp(a) concentration and cardiovascular risk.
• World prevalence of elevated Lp(a).
• Effect and mechanism of action of elevated Lp(a).
• Treatment of elevated Lp(a).
• Effects of lipid-apheresis.